Kinfo
Perspective Therapeutics Inc. logo

Perspective Therapeutics Inc.

CATXNYSEHealthcare·US · USD
$0.86
+0.02 (+2.38%)
Prices as of November 9, 2026 · market closed

Price

Key statistics

Valuation
Market cap97.67M USD
Enterprise value-137.03M USD
Trailing P/E-0.61
Forward P/E-0.83
PEG ratio0.03
Price / sales238.60
Price / book0.30
Profitability
Gross margin0.00%
Operating margin-36120.99%
Profit margin0.00%
Return on assets-22.27%
Return on equity-39.57%
Income (TTM)
Revenue409.00K USD
Gross profit-95.77M USD
EBITDA-121.19M USD
Net income-116.63M USD
Diluted EPS-$1.33
Rev. growth (YoY)-72.10%
Balance sheet
Total cash236.88M USD
Total debt3.96M USD
Debt / equity1.22
Current ratio6.61
Book value / share$2.84
Cash flow (TTM)
Operating cash flow-93.07M USD
Levered free cash flow-69.43M USD
Shares & price
Shares outstanding114.09M
Float70.82M
Held by institutions85.78%
Beta1.99
50-day MA$2.34
200-day MA$3.50
52-week high$6.16
52-week low$0.78
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-08-10-0.27-0.22+18.52%2026-05-11-0.32-0.25+21.88%2026-03-16-0.34-0.51−50.00%2026-02-201.571.50−4.46%2026-01-300.420.36−14.29%
About Perspective Therapeutics Inc.

Perspective Therapeutics Inc. is a radiopharmaceutical company focused on developing and commercializing precision targeted alpha therapies for cancer. The company’s current portfolio centers on treatments and companion imaging agents designed to deliver radiation directly to tumors while helping physicians visualize disease and tailor care. Its programs are built around proprietary lead-212-based technology and a theranostic approach that combines diagnosis and treatment in a single oncology platform. Perspective Therapeutics is active in several cancer areas, including neuroendocrine tumors, metastatic melanoma, and other solid tumors, through its clinical-stage development efforts. The company also works on complementary tools and manufacturing capabilities that support its radiopharmaceutical pipeline and clinical operations. Based in Seattle, Perspective Therapeutics plays a specialized role in the broader oncology market by advancing targeted nuclear medicine approaches for cancer care.

Sector
Healthcare
Industry
Medical Devices
CEO
Mr. Johan M. Spoor
Employees
163
Headquarters
Seattle, WA, United States

Frequently asked questions about Perspective Therapeutics Inc.